# Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke

Study · id `cardio:ct-nct04415164` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04415164](<https://clinicaltrials.gov/study/NCT04415164>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04415164

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 480 participants.

## Technical summary

Registry record NCT04415164. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-29 (actual); primary completion 2022-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 480 participants (planned count; ClinicalTrials.gov record NCT04415164, source copy `cardio:ctgov-nct04415164-2021-04-09`, retrieved 2026-10-26)
- Started: 2020-09-29 (actual) (ClinicalTrials.gov record NCT04415164, source copy `cardio:ctgov-nct04415164-2021-04-09`, retrieved 2026-10-26)
- Primary completion: 2022-10-31 (anticipated) (ClinicalTrials.gov record NCT04415164, source copy `cardio:ctgov-nct04415164-2021-04-09`, retrieved 2026-10-26)
- Completion: 2023-05-31 (anticipated) (ClinicalTrials.gov record NCT04415164, source copy `cardio:ctgov-nct04415164-2021-04-09`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04415164, source copy `cardio:ctgov-nct04415164-2021-04-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04415164-2021-04-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
- Acronym: EXPECT
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Xueshuantong lyophilized powder
- Intervention (Drug): Placebo
- Intervention (Other): Guidelines-based standard care
- Lead sponsor: Dongzhimen Hospital, Beijing
- Lead sponsor class: OTHER
- Collaborator: Tianjin University of Traditional Chinese Medicine
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Dongzhimen Hospital, Beijing (`cardio:org-dongzhimen-hospital-beijing`)

## Provenance

Content hash: 15bd787d250db4e4d9146547a8ce6008b4e2423fe89d21774231b2d9a5574939
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
